Compare Innovative Industrial Properties Inc (IIPR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs Neurocrine Biosciences Inc — how do they compare? Innovative Industrial Properties Inc trades at $63.9 (market cap $1.87B), while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is far larger — about 9.3× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 11.81% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| IIPR | NBIX | |
|---|---|---|
Market Cap | $1.87B | $17.40B |
Sector | Real Estate | Health |
52-Week High | $64.67 | $180.55 |
52-Week Low | $44.58 | $123.10 |
Enterprise Value | $2.25B | $16.49B |
Dividend Yield | 11.81% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
